Clinical Trial Update: A Conversion Study to Assess Safety and Efficacy of a MR4 Based Immunosuppressive Regimen in Stable Kidney Recipients [Phase 3]

View source ↗

Summary

Phase 3 study evaluating safety and efficacy of an MR4-based immunosuppressive regimen in stable kidney transplant recipients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplantation

Drugs mentioned

• MR4-based immunosuppressive regimen

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Transplantation | Phase 3 | Status: COMPLETED